Intelligence · Clinical Pipeline
Théa Pharma Ireland Pipeline
All ClinicalTrials.gov programs at Théa Pharma Ireland — phase, modality, and trial IDs.
- Programs
- 4
Quick answer
Théa Pharma Ireland has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets
Verona Pharma Ireland Limited
Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy
1 trial -
TAMOXENE 20 mg compresse rivestite con film
Verona Pharma Ireland Limited
cystic fibrosis
1 trial -
Teicoplanina Sandoz 200 mg polvere e solvente per soluzione iniettabile o infusione o soluzione orale
Verona Pharma Ireland Limited
cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection
1 trial -
XEOMIN, 100 unità, polvere per soluzione iniettabile
Verona Pharma Ireland Limited
multifocal spasticity of the upper and lower limb due to cerebral palsy
1 trial
Frequently asked questions
How many pipeline programs does Théa Pharma Ireland have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs